ANI Pharma

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ANI Pharma posts record revenues, eyes growth in Rare Disease

ANI Pharmaceuticals delivered robust financial results, showcasing strong revenue growth and EBITDA improvement. The company's focus on Rare Disease and Generics businesses, along with strategic initiatives for 2023, positions it well for continued growth. Challenges in cash flow management and cautious information sharing require attention.

ANI Pharma reports record Q1 revenues, eyes Rare Disease M&A

ANI Pharma (ANIP) delivered strong financial performance in Q1 2023, with record revenues and raised full-year guidance, driven by successful product launches and operational efficiency.
The company's focus on sustainable growth, patient care, and strategic investments in the Rare Disease space position ANI for future success.
While facing challenges such as increased operating expenses and debt obligations, ANI's strengths in revenue growth and market reception of key products provide opportunities for continued expansion.
ANI's commitment to organic deleveraging, cash generation, and potential M&A activities underscore a strategic approach to long-term growth and financial stability.

ANI Pharma reports stellar Q2 results, eyes rare disease expansion

ANI Pharma delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and record EBITDA.
The company's focus on rare diseases and generics, along with a solid financial position, positions it well for future growth.
ANI Pharma faces challenges in maintaining growth momentum and navigating industry competition but has opportunities for expansion.

ANI Pharma reports record Q3 revenues, raises full-year guidance

ANI Pharmaceuticals (ANIP) delivered impressive Q3 results with record revenues and substantial growth in key segments. Despite market challenges, the company's strategic investments and raised guidance signal confidence in future performance and expansion.

ANI Pharmaceuticals reports record 2023 earnings, eyes growth opportunities

ANI Pharmaceuticals delivered a stellar performance in Q4 2023, achieving record revenue and profitability figures, driven by strong sales in key product segments.
While the company faces challenges in maintaining growth rates and navigating market dynamics, ANI Pharmaceuticals is well-positioned to capitalize on opportunities for expansion and innovation.
With a solid financial foundation, diverse product portfolio, and strategic growth outlook for 2024, ANI Pharmaceuticals remains poised for continued success and market leadership in the pharmaceutical industry.

ANI Pharma reports strong Q1 earnings, eyes Rare Disease growth

ANI Pharma's Q1 2024 performance reflects robust revenue growth across key segments, supported by strategic initiatives and a focus on innovation.
While facing challenges in R&D spending variability and supply tailwinds, the company remains well-positioned to capitalize on growth opportunities.
Opportunities lie in expanding the Rare Disease business, exploring new specialties for Cortrophin Gel, and pursuing strategic M&A for sustained growth.
ANI Pharma's prudent approach to capital deployment and confidence in growth through acquisitions underscore a promising outlook for future expansion.

ANI Pharma reports record revenues, announces Alimera acquisition for growth

ANI Pharma delivered a strong Q2 2024 performance with record revenues and significant growth in key product segments.
The proposed acquisition of Alimera Sciences signals ANI's strategic expansion into high-growth commercial products, enhancing its market position.
While facing integration challenges, ANI's raised guidance and focus on accretive EPS from the acquisition highlight a positive outlook for future growth.

ANI Pharmaceuticals (ANIP) reports record Q3 revenues and eyes rare disease growth in 2025

ANI Pharmaceuticals (ANIP) delivered a robust Q3 performance with record revenues and raised full-year guidance, driven by strong growth in Cortrophin Gel and generics business. The company's emphasis on rare diseases and new offerings positions it for continued growth in 2025. While challenges exist in the payer landscape and acquisition integration, ANIP's strategic focus on key specialties offers promising opportunities for expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows:

ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences

BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open.

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why ANI (ANIP) is Poised to Beat Earnings Estimates Again

BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®.

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts Think ANI (ANIP) Is a Good Investment: Is It?

--ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness-- --ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness--

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis

BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, at the Encore Boston Harbor.

ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium

ANI Pharmaceuticals (ANIP) concluded the recent trading session at $69.69, signifying a +0.2% move from its prior day's close.

ANI Pharmaceuticals (ANIP) Rises Yet Lags Behind Market: Some Facts Worth Knowing

BAUDETTE, Minn., March 27, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug (RLD) Levaquin®. The current annual U.S. market for Levofloxacin Oral Solution is approximately $7.1 million, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider.

ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

ANI (ANIP) Is Considered a Good Investment by Brokers: Is That True?

Here is how ANI Pharmaceuticals (ANIP) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Apogee Enterprises

Couchbase

Blue Bird

Collegium Pharmaceutical

Gigacloud Tech

NewLake Capital Partners, Inc.

Palomar

LiveRamp Holdings Inc

RADCOM

The prevailing market sentiment is currently fueled by the allure of "The Magnificent 7" and stocks with high upside potential. Over the last 52 weeks, the S&P 500 is up ~28% compared to the S&P Small-Cap index (~+15%). Small-cap stocks present enticing prospects for growth and value for investors willing to capitalize on calculated risks. The S&P 500 P/E is 25x vs. the S&P Small-Cap at 14.8x.

Top 10 Small-Cap Stocks (SA Quant)

Does ANI Pharmaceuticals (ANIP) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes ANI Pharmaceuticals (ANIP) a Strong Momentum Stock: Buy Now?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Analysts See ANI (ANIP) as a Buy: Should You Invest?

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

ANI Pharmaceuticals, Inc. (ANIP) Q4 2023 Earnings Call Transcript

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, ANI (ANIP) Q4 Earnings: A Look at Key Metrics

BAUDETTE, Minn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and full year ended December 31, 2023.

ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ANI (ANIP), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Unveiling ANI (ANIP) Q4 Outlook: Wall Street Estimates for Key Metrics

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference in Miami Beach as follows:

ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $57.03, representing a +0.92% change from its previous close.

ANI Pharmaceuticals (ANIP) Advances While Market Declines: Some Information for Investors

BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open.

News for ANI Pharma Stock (ANIP)